Ophidion, Inc. and Neuronasal, Inc. Announce Strategic Collaborations to Tackle Parkinson’s Disease, Obesity, and Diabetes via Novel CNS Delivery Platform

15 Dec 2025
www.businesswire.com
Phase 1Oligonucleotide
PASADENA, Calif.--(BUSINESS WIRE)--Ophidion, Inc., a biotechnology company pioneering non-invasive delivery of gene-silencing and large-molecule therapeutics to the brain, and Neuronasal, Inc., a clinical-stage company advancing patented nose-to-brain delivery of therapeutics, today announced a strategic partnership to co-develop multiple therapeutic candidates targeting key pathways in Parkinson’s disease as well as the treatment of obesity and diabetes.
Under the agreement, Ophidion will deploy its proprietary intravenous “Trojan-horse” carrier technology to deliver oligonucleotide payloads and peptide therapeutics across the blood-brain barrier aiming to improve brain exposures and clinical outcomes for multiple candidates involved in Parkinson’s disease pathology, as well as another candidate to treat obesity and diabetes.
The collaboration spans the full liOphidion, Inc.m proof-of-biology through IND (Investigational New Drug) enabling studies. The deal structure includes upfront and developmentNeuronasal, Inc.nts as well as the formation of a joint venture to advance the programs through clinical development once each product reaches the IND stage.Parkinson’s diseaseobesitydiabetes
Several Parkinson’s-related molecular targets will be advanced in parallel, combining Ophidion’s oligonucleotide/gene-silencing, protein and peptide delivery approach.
A single target to treat obesity and diabetes will also be advanced, combining Ophidion’s oligonucleotide/gene-silencing, protein and peptide delivery approach.
The programs are advancing de-risked cargos from pre-clinical proof-of-concept into proof-of-biology studies in relevant pre-clinical models prior to IND-enabling work.
With the selected cargos obesityiverydiabetesms de-risked, the companies anticipate accelerated timelines and improved translational potential for Parkinson’s disease and obesity/diabetes therapies.
“We are excited to partner with Neuronasal and advance these therapeutics with our Central Nervous System (CNS)-delivery platform,” said Yacoub Habib, CEO of Ophidion. “Parkinson’s disease remains a major unmet need, and by tackling multiple targets simultaneously, we believe we can increase the probability of success and speed translation into patients. Additionally, improving the delivery of therapeutics to the brain for obesity and diabetes has the potential to produce better efficacy in this commercially attractive market.”
Thomas I. Bradshaw, CEO of Neuronasal, added: “Neuronasal is excited to add Ophidion’s brain delivery capability to our Parkinson’s disease developParkinson’s diseaser expobesitywdiabetesdion’s CNS delivery platform will enhance our clinical program for disease-modifying therapies.”
Ophidion is an early-stage NeuronasalrmaceuticaNeuronasaldeveloping non-invaOphidionrapeutics for neurodegenerative disoParkinson’s diseaseary carrier technology is designed to deliveOphidionmolecules and oligonucleotides into the brain via intravenous administration. The company is advancing programs in Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. (Ophidion)
Ophidional is a clinical-stage biotechnology company focused on nose-to-brain delivery of therapeuneurodegenerative disordersstem disorders, including Parkinson’s disease and other related CNS diseases. Its intranasal technology is patent-protected and has achieved human pilot proof-of-concept for brain dHuntington’s diseaseysAlzheimer’s diseasetly beParkinson’s diseasese Ophidional trials. (neuronasal.com)
Neuronasal release contains forward-looking statements, including statements about the schedule, benefits, central nervous system disorderscollaboratioParkinson’s diseaserograms. Actual resCNS diseasesfer due to risks inherent in biopharmaceutical development, regulatory uncertainties, and the ability to execute on N-acetylcysteinen.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!